Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2206-2214

  Welkos, S ^a   Pitt, M L M ^a   Martinez, M ^a   Friedlander, A ^a   Vogel, P ^a   Tammariello, R ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Aerosol; Live vaccine; Pigmentation locus; Pla; Plague; Primates; Yersinia pestis

Indexed keywords

PLAGUE VACCINE; PLASMINOGEN ACTIVATOR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CAUSE OF DEATH; CERCOPITHECIDAE; CONTROLLED STUDY; DEATH; EXPERIMENTAL INFECTION; FEMALE; GENE LOCUS; LETHAL DOSE; MALE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PIGMENTATION; PLAGUE; PRIMATE; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINATION; YERSINIA PESTIS;

ADMINISTRATION, INHALATION; ANIMALS; BACTERIAL PROTEINS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; PIGMENTATION; PLAGUE; PLASMINOGEN ACTIVATORS; PRIMATES; VIRULENCE; YERSINIA PESTIS;

EID: 0037157257     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00119-6     Document Type: Article

References (35)

1. Fraction 1 capsular antigen (F1) purification from Yersinia pestis C092 and an Escherichia coli recombinant strain and efficacy against lethal plague challenge
2. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine
3. Studies on immunization against plague
4. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains Yersinia pestis
5. Efficacy of killed whole-cell vaccine against a lethal aerosol challenge of plague in rodents
6. Genetic analysis and modeling of the virulence of Yersinia pestis
7. Construction of defined F1 negative mutants of virulent Yersinia pestis
8. Pathology of experimental pneumonic plague produced by F1-positive and F1-negative Yersinia pestis in African green monkeys
9. Passive immunity to infection with Yersinia sp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen
10. The pigmentation locus of Yersinia pestis KIM6+ is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2
11. Pathogenicity and immunogenic efficacy of a live attenuated plague vaccine in vervet monkeys
12. Plague immunization. Part I. Past and present trends
13. Live, attenuated Yersinia pestis vaccine: Virulent in non-human primates harmless to guinea pigs
14. r phenotypes of yersiniae
15. Update: Human plague India, 1994
16. Plague? India
17. Isolation and identification of Yersinia pestis responsible for the recent plague outbreaks in India
18. Effectiveness of the revaccination of Hamadryas baboons with dried live plague vaccine NIIS and Yersinia pestis fraction 1
19. Design of a Yersinia pestis strain with increased protection
20. A surface protease and the invasive character of plague
21. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092
22. The critical orifice liquid impinger as a sampler for bacterial aerosols
23. The Collison nebulizer, description, performance, applications
24. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis
25. Immune response to Yersinia outer proteins (Yops) and other virulence determinants after experimental plague infection in mice
26. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis
27. The 102-kilobases unstable region of Yersinia pestis comprises a high-pathogenicity island linked to a pigmentation segment which undergoes internal rearrangement
28. Factors promoting acute and chronic diseases caused by Yersiniae
29. Effectiveness of live or killed plague vaccines in man
30. A filtered non-toxic plague vaccine which protects guinea pigs and mice
31. Studies on P. pestis antigens as prophylactic agents
32. Plague immunization. V Indirect evidence for the efficacy of plague vaccine
33. Measuring the efficacy of vaccination in affording protection against plague
34. Immunity in plague: Protection of the vervet (Cercopithecus aethiops) against pneumonic plague by the oral administration of live attenuated Yersinia pestis